Progress in reducing the global impact of cancer is slow, but the Galleri blood test, developed by the American company Grail, has sparked hope. It can detect signals from 50 types of cancer, with a correct identification rate of 62% for individuals with positive results and a specificity of 99.6% for those without cancer. However, 38% of positive results are false alarms, and the sensitivity of the test is only 40.4%, meaning that many cases of cancer could be missed. Although the test could become a useful tool in future screening programs, its high cost and the lack of evidence that its widespread use reduces cancer mortality are important considerations. In conclusion, although preliminary data is promising, the Galleri test is not a complete solution.
Sources
Latest News
23:48
Mark Rutte stated that the Trump-Putin-Xi meeting is “absolutely normal” and is not a cause for concern
23:30
Anthropic closes its stock market debut at $97.17 per share / What this result says about Wall Street’s confidence in artificial intelligence
23:19
Donald Trump intervened by phone at the “Coalition of the Willing” meeting, where he reportedly questioned the continuation of financial and military aid to Kyiv
22:59
Sorin Grindeanu supports expanding the powers of Marian Neacșu, the sole deputy prime minister in the Niculescu Government
22:51
Alexandru Nazare announced the preparation of RoBOOST / The Fund will attract private capital for Romanian companies
See more news